Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of HIV, Gilead and Tibotec (a wholly owned subsidiary of Johnson & Johnson) remain on track to launch three novel treatment options in the next two years - Gilead's Quad (a four drug, one pill, once-daily, regimen), Tibotec's rilpivirine and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir fixed-dose combination product. Together, these products have the potential for combined peak-year sales in excess of $5 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Human Immunodeficiency Virus reveal that, through 2018, Gilead's Quad will earn peak-year sales of up to $2.5 billion and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir will earn peak-year sales of up to $3 billion. Robust uptake of these agents will be driven by their favorable safety and efficacy profiles and convenient dosing which make them ideal products for treatment-naive patients -- the most lucrative segment of the HIV market.

"Gilead and Tibotec continue to make strong progress with their HIV programs. Gilead will bring the first ever quadruple fixed-dosed therapy -- Quad -- to the market and Tibotec will bring a novel NNRTI -- rilpivirine -- to the market by 2011," said Decision Resources Therapeutic Area Director Danielle Drayton, Ph.D. "Additionally, following approval of rilpivirine as a stand-alone therapy, Gilead plans to seek approval for a fixed-dose combination of Tibotec's rilpivirine plus Gilead's Truvada as a follow-on to Gilead's blockbuster Atripla."

The Pharmacor 2010 findings also reveal that, owing to the widespread availability of HIV therapies that are effective and relatively well tolerated, the largest commercial opportunities in this market lie in the development of agents that offer enhanced convenience. Such therapies include coformulations that minimize the number of pills and frequency of dosing, especially therapies that target the large treatment-naive population. Additionally, agents with reduced long-term toxicities can differentiate themselves in the market.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.      For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-296-2597   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-296-2597,
ccomfort@dresources.com

Use of Centocor-Ortho Biotech's Stelara (Ustekinumab) is on an Upswing as Familiarity Increases and Experience With the Product Produces Excellent Outcomes, According to U.S. Dermatologists

View Now